publication . Other literature type . Article . 2015

A Meta-analysis

Yvonne Freund-Levi; Catarina Oliveira; Kristian Steen frederiksen; Dag Aarsland; Pieter Jelle Visser; Wiesje van der Flier; enrica null; Vincent Camus; Daniel Alcolea; Niklas Mattsson; ...
Open Access English
  • Published: 19 May 2015
Abstract
Abstract<br/>IMPORTANCE:<br/>Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.<br/>OBJECTIVE:<br/>To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).<br/>DATA SOURCES:<br/>Relevant biomarker studies identified by searching studies published befor...
Subjects
Medical Subject Headings: mental disorders
free text keywords: genetics [Apolipoprotein E4], analysis [Amyloid beta-Peptides], analysis [Biological Markers], pathology [Brain], chemistry [Cerebrospinal Fluid], pathology [Dementia], pathology [Mild Cognitive Impairment], Neurology, Adult; Age Factors; Aged; Aged, 80 and over; Amyloid beta-Peptides/analysis; Apolipoprotein E4/genetics; Biological Markers/analysis; Brain/pathology; Cerebrospinal Fluid/chemistry; Dementia/pathology; Female; Genotype; Humans; Male; Middle Aged; Mild Cognitive Impairment/pathology; Positron-Emission Tomography; Prevalence; Risk Factors, Article
Funded by
SNSF| Macrophage migration inhibitory factor and neuroinflammation in early Alzheimer’s Disease
Project
  • Funder: Swiss National Science Foundation (SNSF)
  • Project Code: 320030L_141179
  • Funding stream: Project funding | Project funding (Div. I-III)
,
NIH| Imaging, Methodology and Statistics Core
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P01AG025204-06
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| DIAN Genetics Core
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5U19AG032438-03
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| AMYLOID PATHOLOGY AND COGNITION IN NORMAL ELDERLY
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R37AG025516-03
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| Role of LRP &its ligand tPA in LTP &aging
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5P50AG005681-19
  • Funding stream: NATIONAL INSTITUTE ON AGING
48 references, page 1 of 4

1. World Health Organization. Dementia: a public health priority. http://www.who.int/mental_health /publications/dementia_report_2012/en/. Accessed April 27, 2015.

2. Bateman RJ, Xiong C, Benzinger TL, et al; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9): 795-804.

3. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron. 2013;80(6):1347-1358.

4. Fagan AM, Xiong C, Jasielec MS, et al; Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014;6(226):226ra30.

5. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 280-292. [OpenAIRE]

6. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629.

7. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33.

8. Murayama S, Saito Y. Neuropathological diagnostic criteria for Alzheimer's disease. Neuropathology. 2004;24(3):254-260.

9. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834-841.

10. Lin Y-T, Cheng J-T, Yao Y-C, et al. Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease. J Alzheimers Dis. 2009;18 (4):907-918.

11. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.

12. Randall C, Mosconi L, de Leon M, Glodzik L. Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed). 2013;18:1150-1173.

13. Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32(suppl 1):S20-S36. [OpenAIRE]

14. Vandenbroucke JP, von Elm E, Altman DG, et al; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805-835. [OpenAIRE]

15. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25. [OpenAIRE]

48 references, page 1 of 4
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue